Abbott Laboratories (ABT) is drawing fresh scrutiny after sales declines in its Nutrition business, new product launches and pricing moves, and early signs of recovering volumes, all while analysts grow more cautious on the stock.
See our latest analysis for Abbott Laboratories.
The share price has come under pressure despite the Exact Sciences acquisition and commentary around legal risks. The stock is down 16.83% on a 1 month share price return, and the 1 year total shareholder return has…
See our latest analysis for Abbott Laboratories.
The share price has come under pressure despite the Exact Sciences acquisition and commentary around legal risks. The stock is down 16.83% on a 1 month share price return, and the 1 year total shareholder return has…
